CSPG4 and melanoma: Indeed, initial longitudinal study of CTC heterogeneity in 10 stage IV melanoma patients suggested that expression of CSPG4 on CTCs may be downregulated in response to BRAF and mitogen-activated protein kinase kinase (MEK)-inhibiting therapy (Tsao et al., 2018).